Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 13/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.69 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.62 |
| ▸ | SRC | P12931 | 4/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767287 | 0.92 | MAP3K8 (0.75) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4773950 | 0.92 | MAP3K8 (0.74) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5124439 | 0.87 | MAP3K8 (0.73) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4904414 | 0.87 | MAP3K8 (0.82) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4769727 | 0.87 | MAP3K8 (0.79) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5118168 | 0.84 | MAP3K8 (0.85) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5118384 | 0.84 | MAP3K8 (0.85) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5124454 | 0.84 | MAP3K8 (0.79) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5116860 | 0.83 | MAP3K8 (0.70) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5111372 | 0.83 | MAP3K8 (0.67) | MAP3K8MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | MAP3K8 99/4885MAPK13 404/4885MAPK12 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.